Barclays’s TriSalus Life Sciences TLSI Stock Holding History

Barclays’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23K	Sell	5,741 -41,958	-88%	-$205K	﹤0.01%	4553
2025 Q4	$333K	Buy	47,699 +21,231	+80%	+$119K	﹤0.01%	4078
2025 Q3	$123K	Sell	26,468 -3,469	-12%	-$16.2K	﹤0.01%	4552
2025 Q2	$163K	Buy	29,937 +29,905	+93,453%	+$160K	﹤0.01%	4387
2025 Q1	$177	Buy	+32	New	+$170	﹤0.01%	5119
2022 Q4	–	Sell	-296,422	Closed	-$2.94M	–	5371
2022 Q3	$2.94M	Buy	296,422 +94,012	+46%	+$930K	﹤0.01%	1489
2022 Q2	$1.99M	Buy	202,410 +194,264	+2,385%	+$1.91M	﹤0.01%	1852
2022 Q1	$80K	Buy	+8,146	New	+$80.4K	﹤0.01%	3895

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

Barclays's TLSI Position: Q1 2026 in Review

Barclays reduced its TriSalus Life Sciences (TLSI) stake by 88% in Q1 2026, selling an estimated $205K and leaving 5,741 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #4553.

Barclays first reported a position in TLSI in Q1 2022 and has held it in 8 quarters since. The position peaked at $2.94M in Q3 2022. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

Barclays held 5,741 shares of TriSalus Life Sciences worth $23K as of Q1 2026.
Barclays sold 41,958 TriSalus Life Sciences shares in Q1 2026, an estimated $205K.
TriSalus Life Sciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4553 holding.
Barclays first reported a position in TriSalus Life Sciences in Q1 2022 and has held it in 8 quarters since.
Barclays's TriSalus Life Sciences position peaked at $2.94M in Q3 2022.
84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.